Medtronic plc (MDT) 10-Year Financial Performance & Capital Metrics

MDT • • Industrial / General

HealthcareMedical DevicesCardiovascular DevicesCardiac Ablation & Electrophysiology

AboutMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.Show more

Revenue $33.54B +3.6%
EBITDA $8.82B +13.2%
Net Income $4.66B +26.8%
EPS (Diluted) 3.61 +30.8%
Gross Margin 65.32%
EBITDA Margin 26.29% +9.2%
Operating Margin 17.76% +11.7%
Net Margin 13.9% +22.4%
ROE 9.45% +31.2%
ROIC 6.01% +15.7%
Debt/Equity 0.59 +19.1%
Interest Coverage 8.17 +14.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Dividend Aristocrat: 36 years of consecutive increases
✓FCF machine: 15.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.9%
✓Share count reduced 3.0% through buybacks
✓Healthy 5Y average net margin of 13.0%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.17%

5Y3.01%

3Y1.91%

TTM5.34%

Profit (Net Income) CAGR

10Y5.71%

5Y-0.54%

3Y-2.56%

TTM11.12%

EPS CAGR

10Y4.12%

5Y0.39%

3Y-1.08%

TTM13.46%

ROCE

10Y Avg6.65%

5Y Avg6.65%

3Y Avg6.92%

Latest7.54%

Peer Comparison

Cardiac Ablation & Electrophysiology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BSXBoston Scientific Corporation	139.56B	94.14	75.31	17.61%	13.53%	11.04%	1.9%	0.51
MDTMedtronic plc	123.61B	96.42	26.71	3.62%	13.71%	9.75%	4.19%	0.59
ITGRInteger Holdings Corporation	2.9B	82.74	24.34	10.35%	4.75%	4.98%	3.44%	0.68
ADGMAdagio Medical Holdings, Inc.	18.68M	0.88	-0.25	-10.33%	-199.86%	-270%		0.82
VTAKCatheter Precision, Inc.	3.42M	2.05	-0.31	-4.98%	-23.81%	-269.53%		0.15

Profit & Loss

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Sales/Revenue+	28.83B	29.71B	29.95B	30.56B	28.91B	30.12B	31.69B	31.23B	32.36B	33.54B
Revenue Growth %	0.42%	0.03%	0.01%	0.02%	-0.05%	0.04%	0.05%	-0.01%	0.04%	0.04%
Cost of Goods Sold+	9.14B	9.29B	9.07B	9.15B	9.42B	10.48B	10.14B	10.72B	11.22B	11.63B
COGS % of Revenue	0.32%	0.31%	0.3%	0.3%	0.33%	0.35%	0.32%	0.34%	0.35%	0.35%
Gross Profit+	19.69B	20.42B	20.89B	21.4B	19.49B	19.63B	21.54B	20.51B	21.15B	21.91B
Gross Margin %	0.68%	0.69%	0.7%	0.7%	0.67%	0.65%	0.68%	0.66%	0.65%	0.65%
Gross Profit Growth %	0.41%	0.04%	0.02%	0.02%	-0.09%	0.01%	0.1%	-0.05%	0.03%	0.04%
Operating Expenses+	14.33B	15.03B	14.25B	15.13B	14.7B	15.15B	15.79B	15.02B	16B	15.95B
OpEx % of Revenue	0.5%	0.51%	0.48%	0.5%	0.51%	0.5%	0.5%	0.48%	0.49%	0.48%
Selling, General & Admin	9.47B	10.02B	10.24B	10.42B	10.11B	10.15B	10.29B	10.41B	10.74B	10.85B
SG&A % of Revenue	0.33%	0.34%	0.34%	0.34%	0.35%	0.34%	0.32%	0.33%	0.33%	0.32%
Research & Development	2.22B	2.19B	2.26B	2.33B	2.33B	2.49B	2.75B	2.7B	2.73B	2.73B
R&D % of Revenue	0.08%	0.07%	0.08%	0.08%	0.08%	0.08%	0.09%	0.09%	0.08%	0.08%
Other Operating Expenses	2.64B	2.82B	1.75B	2.39B	2.26B	2.51B	2.75B	1.91B	2.53B	2.37B
Operating Income+	5.36B	5.38B	6.64B	6.27B	4.79B	4.48B	5.75B	5.49B	5.14B	5.96B
Operating Margin %	0.19%	0.18%	0.22%	0.21%	0.17%	0.15%	0.18%	0.18%	0.16%	0.18%
Operating Income Growth %	0.42%	0%	0.23%	-0.06%	-0.24%	-0.06%	0.28%	-0.05%	-0.06%	0.16%
EBITDA+	8.18B	8.3B	9.28B	8.93B	7.45B	7.19B	8.46B	8.18B	7.79B	8.82B
EBITDA Margin %	0.28%	0.28%	0.31%	0.29%	0.26%	0.24%	0.27%	0.26%	0.24%	0.26%
EBITDA Growth %	0.61%	0.01%	0.12%	-0.04%	-0.17%	-0.04%	0.18%	-0.03%	-0.05%	0.13%
D&A (Non-Cash Add-back)	2.82B	2.92B	2.64B	2.66B	2.66B	2.7B	2.71B	2.7B	2.65B	2.86B
EBIT	5.72B	5.7B	6.82B	6.64B	5.15B	4.82B	6.07B	6B	5.56B	6.36B
Net Interest Income+	-955M	-1.09B	-1.15B	-1.44B	-1.09B	-925M	-553M	-636M	-719M	-729M
Interest Income	431M	0	0	0	0	0	0	0	0	0
Interest Expense	1.39B	1.09B	1.15B	1.44B	1.09B	925M	553M	636M	719M	729M
Other Income/Expense	-1.02B	-781M	-965M	-1.07B	-736M	-589M	-235M	-121M	-307M	-327M
Pretax Income+	4.34B	4.6B	5.67B	5.2B	4.05B	3.9B	5.52B	5.36B	4.84B	5.63B
Pretax Margin %	0.15%	0.15%	0.19%	0.17%	0.14%	0.13%	0.17%	0.17%	0.15%	0.17%
Income Tax+	798M	578M	2.58B	547M	-751M	265M	456M	1.58B	1.13B	936M
Effective Tax Rate %	0.82%	0.88%	0.55%	0.89%	1.18%	0.93%	0.91%	0.7%	0.76%	0.83%
Net Income+	3.54B	4.03B	3.1B	4.63B	4.79B	3.61B	5.04B	3.76B	3.68B	4.66B
Net Margin %	0.12%	0.14%	0.1%	0.15%	0.17%	0.12%	0.16%	0.12%	0.11%	0.14%
Net Income Growth %	0.32%	0.14%	-0.23%	0.49%	0.03%	-0.25%	0.4%	-0.25%	-0.02%	0.27%
Net Income (Continuing)	3.54B	4.02B	3.1B	4.65B	4.81B	3.63B	5.06B	3.78B	3.7B	4.69B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	122M	102M	121M	135M	174M	171M	182M	206M	232M
EPS (Diluted)+	2.48	2.89	2.27	3.41	3.54	2.66	3.73	2.82	2.76	3.61
EPS Growth %	0.03%	0.17%	-0.21%	0.5%	0.04%	-0.25%	0.4%	-0.24%	-0.02%	0.31%
EPS (Basic)	2.51	2.92	2.29	3.44	3.57	2.68	3.75	2.83	2.77	3.63
Diluted Shares Outstanding	1.43B	1.39B	1.37B	1.36B	1.35B	1.35B	1.35B	1.33B	1.33B	1.29B
Basic Shares Outstanding	1.41B	1.38B	1.36B	1.35B	1.34B	1.34B	1.34B	1.33B	1.33B	1.29B
Dividend Payout Ratio	0.6%	0.59%	0.8%	0.58%	0.6%	0.87%	0.67%	0.96%	1%	0.77%

Balance Sheet

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Total Current Assets+	23.6B	24.87B	22.98B	21.97B	22.03B	22.55B	23.06B	21.68B	21.93B	23.81B
Cash & Short-Term Investments	12.63B	13.71B	11.23B	9.85B	10.95B	10.82B	10.57B	7.96B	8.01B	8.96B
Cash Only	2.88B	4.97B	3.67B	4.39B	4.14B	3.59B	3.71B	1.54B	1.28B	2.22B
Short-Term Investments	9.76B	8.74B	7.56B	5.46B	6.81B	7.22B	6.86B	6.42B	6.72B	6.75B
Accounts Receivable	5.56B	5.59B	5.99B	6.22B	4.64B	5.46B	5.55B	6B	6.13B	6.51B
Days Sales Outstanding	70.41	68.69	72.96	74.32	58.64	66.2	63.94	70.11	69.11	70.91
Inventory	3.47B	3.34B	3.58B	3.75B	4.23B	4.31B	4.62B	5.29B	5.22B	5.48B
Days Inventory Outstanding	138.66	131.09	144.08	149.63	163.79	150.17	166.08	180.24	169.78	171.83
Other Current Assets	833M	2.24B	2.19B	2.14B	2.21B	1.96B	2.32B	2.42B	2.58B	2.86B
Total Non-Current Assets+	76.04B	74.98B	68.41B	67.73B	68.66B	70.53B	67.92B	69.27B	68.05B	67.86B
Property, Plant & Equipment	4.84B	4.36B	4.6B	4.67B	4.83B	5.22B	5.41B	5.57B	6.13B	6.84B
Fixed Asset Turnover	5.96x	6.81x	6.51x	6.54x	5.99x	5.77x	5.85x	5.61x	5.28x	4.91x
Goodwill	41.27B	38.52B	39.54B	39.96B	39.84B	41.96B	40.5B	41.42B	40.99B	41.74B
Intangible Assets	26.9B	23.41B	21.72B	20.56B	19.06B	17.74B	15.59B	14.84B	13.22B	11.67B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.8B	8.7B	2.54B	2.53B	4.93B	5.61B	6.41B	7.44B	7.7B	7.62B
Total Assets+	99.55B	99.82B	91.39B	89.69B	90.69B	93.08B	90.98B	90.95B	89.98B	91.68B
Asset Turnover	0.29x	0.30x	0.33x	0.34x	0.32x	0.32x	0.35x	0.34x	0.36x	0.37x
Asset Growth %	-0.07%	0%	-0.08%	-0.02%	0.01%	0.03%	-0.02%	-0%	-0.01%	0.02%
Total Current Liabilities+	7.17B	14.26B	10.08B	8.47B	10.37B	8.51B	12.39B	9.05B	10.79B	12.88B
Accounts Payable	1.71B	1.55B	1.63B	1.95B	2B	2.11B	2.28B	2.66B	2.41B	2.45B
Days Payables Outstanding	68.23	61.07	65.54	77.86	77.31	73.33	81.89	90.65	78.43	76.85
Short-Term Debt	993M	7.52B	2.06B	832M	2.77B	2M	3.74B	13M	1.09B	2.87B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.71B	1.94B	1.99B	2.19B	2.1B	2.48B	2.12B	1.95B	2.38B	2.52B
Current Ratio	3.29x	1.74x	2.28x	2.59x	2.13x	2.65x	1.86x	2.39x	2.03x	1.85x
Quick Ratio	2.81x	1.51x	1.92x	2.15x	1.72x	2.14x	1.49x	1.81x	1.55x	1.42x
Cash Conversion Cycle	140.84	138.71	151.5	146.09	145.12	143.04	148.13	159.7	160.46	165.89
Total Non-Current Liabilities+	40.55B	35.18B	30.49B	31.01B	29.45B	32.97B	25.86B	30.23B	28.77B	30.55B
Long-Term Debt	29.99B	25.86B	23.68B	24.47B	21.98B	26.32B	20.32B	24.29B	23.88B	25.59B
Capital Lease Obligations	26M	23M	21M	10M	45M	62M	56M	57M	55M	52M
Deferred Tax Liabilities	3.73B	2.98B	1.42B	1.28B	1.17B	1.03B	884M	708M	515M	403M
Other Non-Current Liabilities	6.67B	6.4B	5.36B	5.25B	6.26B	5.57B	4.61B	5.18B	4.33B	4.5B
Total Liabilities	47.72B	49.4B	40.57B	39.48B	39.82B	41.48B	38.26B	39.28B	39.56B	43.42B
Total Debt+	31.01B	33.4B	25.76B	25.32B	24.8B	26.39B	24.11B	24.36B	25.02B	28.52B
Net Debt	28.14B	28.43B	22.09B	20.92B	20.66B	22.8B	20.4B	22.82B	23.74B	26.3B
Debt / Equity	0.60x	0.66x	0.51x	0.50x	0.49x	0.51x	0.46x	0.47x	0.50x	0.59x
Debt / EBITDA	3.79x	4.02x	2.77x	2.84x	3.33x	3.67x	2.85x	2.98x	3.21x	3.23x
Net Debt / EBITDA	3.44x	3.43x	2.38x	2.34x	2.77x	3.17x	2.41x	2.79x	3.05x	2.98x
Interest Coverage	3.87x	4.92x	5.79x	4.34x	4.39x	4.85x	10.40x	8.62x	7.15x	8.17x
Total Equity+	51.83B	50.42B	50.82B	50.21B	50.87B	51.6B	52.72B	51.66B	50.42B	48.26B
Equity Growth %	-0.03%	-0.03%	0.01%	-0.01%	0.01%	0.01%	0.02%	-0.02%	-0.02%	-0.04%
Book Value per Share	36.35	36.23	37.15	36.99	37.65	38.11	39.01	38.76	37.90	37.41
Total Shareholders' Equity	51.83B	50.29B	50.72B	50.09B	50.74B	51.43B	52.55B	51.48B	50.21B	48.02B
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	21.7B	23.36B	24.38B	26.27B	28.13B	28.59B	30.25B	30.39B	30.4B	31.48B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-1.87B	-2.61B	-1.79B	-2.71B	-3.56B	-3.48B	-2.27B	-3.5B	-3.32B	-4.28B
Minority Interest	0	122M	102M	121M	135M	174M	171M	182M	206M	232M

Cash Flow

	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Cash from Operations+	5.22B	6.88B	4.68B	7.01B	7.23B	6.24B	7.35B	6.04B	6.79B	7.04B
Operating CF Margin %	0.18%	0.23%	0.16%	0.23%	0.25%	0.21%	0.23%	0.19%	0.21%	0.21%
Operating CF Growth %	0.06%	0.32%	-0.32%	0.5%	0.03%	-0.14%	0.18%	-0.18%	0.12%	0.04%
Net Income	3.54B	4.02B	3.1B	4.65B	4.81B	3.63B	5.06B	3.78B	3.68B	4.69B
Depreciation & Amortization	2.82B	2.92B	2.64B	2.66B	2.66B	2.7B	2.71B	2.7B	2.65B	2.86B
Stock-Based Compensation	376M	348M	344M	290M	297M	344M	359M	355M	393M	429M
Deferred Taxes	-460M	-459M	-919M	-304M	-1.31B	-422M	-604M	-226M	-508M	-316M
Other Non-Cash Items	34M	-89M	-307M	792M	722M	687M	711M	396M	1.06B	433M
Working Capital Changes	-1.09B	139M	-173M	-1.08B	61M	-701M	-889M	-967M	-484M	-1.05B
Change in Receivables	-435M	-75M	-275M	-581M	1.29B	-761M	-477M	-576M	-391M	-433M
Change in Inventory	-186M	-227M	-192M	-274M	-577M	78M	-560M	-939M	-139M	-292M
Change in Payables	-65M	356M	65M	399M	-44M	531M	213M	696M	391M	209M
Cash from Investing+	2.25B	-1.57B	5.86B	-774M	-3.2B	-2.87B	-1.66B	-3.49B	-2.37B	-1.94B
Capital Expenditures	-1.05B	-1.25B	-1.07B	-1.13B	-1.21B	-1.35B	-1.37B	-1.46B	-1.59B	-1.86B
CapEx % of Revenue	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.05%	0.05%	0.06%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-14M	22M	-22M	36M	-37M	-54M	-10M	4M	-261M	-249M
Cash from Financing+	-9.54B	-3.28B	-11.95B	-5.43B	-4.2B	-4.14B	-5.34B	-4.96B	-4.45B	-4.36B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.14B	-2.38B	-2.49B	-2.69B	-2.89B	-3.12B	-3.38B	-3.62B	-3.67B	-3.59B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	60M	26M	-94M	14M	581M	206M	163M	-101M	-3M	-184M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	4.17B	5.63B	3.62B	5.87B	6.02B	4.88B	5.98B	4.58B	5.2B	5.18B
FCF Margin %	0.14%	0.19%	0.12%	0.19%	0.21%	0.16%	0.19%	0.15%	0.16%	0.15%
FCF Growth %	-0.04%	0.35%	-0.36%	0.62%	0.03%	-0.19%	0.22%	-0.23%	0.14%	-0%
FCF per Share	2.93	4.04	2.64	4.33	4.46	3.61	4.42	3.44	3.91	4.02
FCF Conversion (FCF/Net Income)	1.47x	1.71x	1.51x	1.51x	1.51x	1.73x	1.46x	1.61x	1.85x	1.51x
Interest Paid	1.27B	1.13B	1.15B	973M	643M	582M	540M	606M	826M	762M
Taxes Paid	1.38B	1.03B	2.54B	1.56B	878M	1.25B	996M	1.55B	1.62B	1.82B

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	6.74%	7.88%	6.13%	9.17%	9.48%	7.04%	9.66%	7.2%	7.2%	9.45%
Return on Invested Capital (ROIC)	4.89%	5.08%	6.56%	6.53%	5.04%	4.61%	5.85%	5.57%	5.19%	6.01%
Gross Margin	68.29%	68.72%	69.73%	70.04%	67.41%	65.19%	67.98%	65.67%	65.34%	65.32%
Net Margin	12.27%	13.56%	10.36%	15.16%	16.56%	11.97%	15.9%	12.03%	11.36%	13.9%
Debt / Equity	0.60x	0.66x	0.51x	0.50x	0.49x	0.51x	0.46x	0.47x	0.50x	0.59x
Interest Coverage	3.87x	4.92x	5.79x	4.34x	4.39x	4.85x	10.40x	8.62x	7.15x	8.17x
FCF Conversion	1.47x	1.71x	1.51x	1.51x	1.51x	1.73x	1.46x	1.61x	1.85x	1.51x
Revenue Growth	42.31%	3.04%	0.82%	2.02%	-5.38%	4.16%	5.21%	-1.45%	3.64%	3.62%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Cardiac and Vascular Group	10.2B	10.5B	11.35B	11.51B	10.47B	-	11.42B	11.57B	11.83B	12.48B
Cardiac and Vascular Group Growth	-	2.96%	8.15%	1.33%	-9.01%	-	-	1.31%	2.23%	5.49%
Neuroscience Group	-	-	-	-	-	-	8.78B	8.96B	9.41B	9.85B
Neuroscience Group Growth	-	-	-	-	-	-	-	1.99%	4.99%	4.68%
Medical Surgical	-	-	-	-	-	-	9.14B	8.43B	8.42B	8.41B
Medical Surgical Growth	-	-	-	-	-	-	-	-7.75%	-0.19%	-0.12%
Diabetes Group	1.86B	1.93B	2.14B	2.39B	2.37B	-	2.34B	2.26B	2.49B	2.75B
Diabetes Group Growth	-	3.38%	11.05%	11.73%	-0.96%	-	-	-3.25%	9.99%	10.73%
Cardiovascular Portfolio	-	-	-	-	-	10.77B	-	-	-	-
Cardiovascular Portfolio Growth	-	-	-	-	-	-	-	-	-	-
Medical Surgical Portfolio	-	-	-	-	-	8.74B	-	-	-	-
Medical Surgical Portfolio Growth	-	-	-	-	-	-	-	-	-	-
Neuroscience Portfolio	-	-	-	-	-	8.2B	-	-	-	-
Neuroscience Portfolio Growth	-	-	-	-	-	-	-	-	-	-
Diabetes Operating Unit	-	-	-	-	-	2.41B	-	-	-	-
Diabetes Operating Unit Growth	-	-	-	-	-	-	-	-	-	-
Minimally Invasive Therapies Group	-	-	8.72B	8.48B	8.35B	-	-	-	-	-
Minimally Invasive Therapies Group Growth	-	-	-	-2.73%	-1.49%	-	-	-	-	-
Restorative Therapies Group	-	-	7.74B	8.18B	7.72B	-	-	-	-	-
Restorative Therapies Group Growth	-	-	-	5.68%	-5.60%	-	-	-	-	-

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
UNITED STATES	17.58B	34.64B	15.88B	16.19B	14.92B	15.53B	16.13B	16.37B	16.56B	17.17B
UNITED STATES Growth	-	97.06%	-54.17%	2.01%	-7.87%	4.05%	3.92%	1.48%	1.15%	3.68%
Total Other Countries, Excluding United States and Ireland	-	-	13.99B	14.27B	13.91B	14.49B	15.45B	14.76B	15.69B	16.25B
Total Other Countries, Excluding United States and Ireland Growth	-	-	-	1.99%	-2.54%	4.18%	6.62%	-4.49%	6.32%	3.58%
IRELAND	-	-	85M	91M	85M	100M	101M	98M	113M	116M
IRELAND Growth	-	-	-	7.06%	-6.59%	17.65%	1.00%	-2.97%	15.31%	2.65%
EMEA	6.7B	6.74B	-	-	-	-	-	-	-	-
EMEA Growth	-	0.58%	-	-	-	-	-	-	-	-
Asia Pacific	3.06B	3.44B	-	-	-	-	-	-	-	-
Asia Pacific Growth	-	12.52%	-	-	-	-	-	-	-	-
CHINA	1.5B	1.59B	-	-	-	-	-	-	-	-
CHINA Growth	-	6.29%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Medtronic plc (MDT) has a price-to-earnings (P/E) ratio of 26.7x. This suggests investors expect higher future growth.

Growth & Financials

Medtronic plc (MDT) reported $34.76B in revenue for fiscal year 2025. This represents a 115% increase from $16.18B in 2012.

Medtronic plc (MDT) grew revenue by 3.6% over the past year. Growth has been modest.

Yes, Medtronic plc (MDT) is profitable, generating $4.76B in net income for fiscal year 2025 (13.9% net margin).

Dividend & Returns

Yes, Medtronic plc (MDT) pays a dividend with a yield of 2.89%. This makes it attractive for income-focused investors.

Medtronic plc (MDT) has a return on equity (ROE) of 9.4%. This is below average, suggesting room for improvement.

Medtronic plc (MDT) generated $5.21B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...